Synapse - Alexander Drilon

Results (631)

NTRK fusion detection across three assays and 29,000 tumors

Meeting Abstract

Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
Modern Pathology (2019)

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

Review

Gelatti, A. C. Z.; Drilon, A.; Santini, F. C.
Lung Cancer (2019)

Fulltext@MSK | Save

A phase Ib/II study of ramucirumab in combination with emibetuzumab in patients with advanced cancer

Journal Article

Harding, J. J.; Zhu, A. X.; Bauer, T. M.; Choueiri, T. K.; Drilon, A.; Voss, M. H.; Fuchs, C. S.; Abou-Alfa, G. K.; Wijayawardana, S. R.; Wang, X. A.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

NTRK fusion detection across three assays and 29,000 tumors

Meeting Abstract

Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
Laboratory Investigation (2019)

Fulltext@MSK | Save

Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers

Meeting Abstract

Meric-Bernstam, F.; Shukla, N.; Peled, N.; Landman, Y.; Onitilo, A.; Montez, S.; Ku, N. C.; Hyman, D. M.; Drilon, A.; Hong, D. S.
Cancer Research (2019)

Fulltext@MSK | Save

Activity of larotrectinib in TRK fusion lung cancer

Meeting Abstract

Drilon, A.; Kummar, S.; Moreno, V.; Patel, J.; Lassen, U.; Rosen, L.; Childs, B. H.; Nanda, S.; Cox, M. C.; Ku, N. C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Meeting Abstract

Barlesi, F.; Drilon, A.; De Braud, F.; Cho, B. C.; Ahn, M. J.; Siena, S.; Krebs, M. G.; Lin, C. C.; John, T.; Tan, D. S. W.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden

Journal Article

Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halpenny, D.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: Data from a tri-institutional cohort of the Lung Cancer Mutation Consortium